newrepublic.com

A major asthma drugmaker has been quietly investing in coal on the side.

The pharmaceutical company that just months ago was embroiled in a price-gouging scandal over its life-saving EpiPen now finds itself at the center of another potential controversy. According to Reuters’ Michael Erman, Mylan N.V. has for the last six years been buying up refined coal in order to reduce its tax bill and boost its bottom line:Since 2011, Mylan has bought 99 percent stakes in five co...